AMPLIFY
2013
Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis
In 5,395 patients with acute venous thromboembolism, apixaban was non-inferior to conventional heparin–warfarin therapy for recurrent VTE, with far less major bleeding.
Result
- Absolute difference
- 0.4 points
The absolute difference is derived from the event rates.
Also reported: Major bleeding 0.6 % vs 1.8 % (RR 0.31).
- Subtopic
- Venous thromboembolism
- Design
- Double-blind, double-dummy RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ESC 2019 Pulmonary Embolism
- Source
- Agnelli G, et al. N Engl J Med. 2013;369(9):799-808.doi 10.1056/NEJMoa1302507
Discussion & critique
A single-drug oral regimen with no heparin lead-in. The 69 % reduction in major bleeding is the headline; AMPLIFY-EXT extended the low-dose secondary-prevention story.